The Combat Methamphetamine Epidemic Act of 2005 limits the sales of which substances?

The Combat Methamphetamine Epidemic Act of 2005 specifically targets over-the-counter (OTC) products that contain pseudoephedrine, ephedrine, and phenylpropanolamine. The act was enacted in response to the growing concern over the illegal manufacture of methamphetamine, which often involves the use of these substances in their production.

Under this law, the sale of these ingredients is restricted. This means that retailers must keep them behind the counter or in a locked cabinet and may only sell them in limited quantities. Additionally, purchasers are required to provide identification, and sales are recorded to monitor for potential abuse.

This regulatory framework specifically addresses the components often associated with methamphetamine synthesis, making option A the clear correct choice. Other options address different categories of medications but do not pertain to the specific restrictions laid out in the Combat Methamphetamine Epidemic Act. For example, controlled substances and prescription medications are regulated under different legal frameworks, while not all OTC medications are restricted under this act.